Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

586 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Dinh M, Soong D, Noguchi H, Buchbjerg JK, Favaro E, Fukuhara N. Izutsu K, et al. Among authors: ishizawa k. Cancer Sci. 2023 Dec;114(12):4643-4653. doi: 10.1111/cas.15996. Epub 2023 Nov 3. Cancer Sci. 2023. PMID: 37921363 Free PMC article.
Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study.
Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, Amano M, Ishida T, Uike N, Utsunomiya A, Ohshima K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K, Tsukasaki K. Imaizumi Y, et al. Among authors: ishizawa k. Int J Hematol. 2023 Feb;117(2):206-215. doi: 10.1007/s12185-022-03473-y. Epub 2022 Oct 29. Int J Hematol. 2023. PMID: 36308678
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.
Tahir SK, Calvo E, Carneiro BA, Yuda J, Shreenivas A, Jongen-Lavrencic M, Gort E, Ishizawa K, Morillo D, Biesdorf C, Smith M, Cheng D, Motwani M, Sharon D, Uziel T, Modi DA, Buchanan FG, Morgan-Lappe S, Medeiros BC, Phillips DC. Tahir SK, et al. Among authors: ishizawa k. Blood. 2023 Apr 27;141(17):2114-2126. doi: 10.1182/blood.2022017333. Blood. 2023. PMID: 36720090 Free PMC article.
Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL.
Onishi Y, Furukawa E, Kamata M, Fukatsu M, Kameoka Y, Hatta S, Hamada H, Oyake T, Kai T, Sukegawa M, Nakajima S, Yanagiya R, Yamaguchi K, Takahashi T, Harazaki Y, Izumi T, Murai K, Ito S, Ikezoe T, Ishizawa K, Takahashi N, Harigae H. Onishi Y, et al. Among authors: ishizawa k. Int J Hematol. 2023 May;117(5):738-747. doi: 10.1007/s12185-023-03546-6. Epub 2023 Feb 9. Int J Hematol. 2023. PMID: 36757523
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
Asada N, Ando J, Takada S, Yoshida C, Usuki K, Shinagawa A, Ishizawa K, Miyamoto T, Iida H, Dobashi N, Okubo S, Honda H, Soshin T, Nishimura Y, Tsutsui A, Mukai H, Yamamoto K. Asada N, et al. Among authors: ishizawa k. Jpn J Clin Oncol. 2023 Jun 29;53(7):595-603. doi: 10.1093/jjco/hyad027. Jpn J Clin Oncol. 2023. PMID: 37017320 Free PMC article. Clinical Trial.
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Sunami K, Fuchida SI, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Imada K, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Onishi R, Tada K, Iida S. Sunami K, et al. Among authors: ishizawa k. Hematol Oncol. 2023 Aug;41(3):442-452. doi: 10.1002/hon.3105. Epub 2022 Dec 15. Hematol Oncol. 2023. PMID: 36433829 Clinical Trial.
The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin-transferrin receptor 1 axis.
Kameda K, Yanagiya R, Miyatake Y, Carreras J, Higuchi H, Murayama H, Ishida T, Ito A, Iida S, Fukuhara N, Harigae H, Fujioka Y, Takahashi N, Wada H, Ishida F, Nakazawa H, Ishihara R, Murakami Y, Tagawa H, Matsuura T, Nakagawa S, Iwabuchi S, Hashimoto S, Imadome KI, Nakamura N, Ishizawa K, Kanda Y, Ando K, Kotani A. Kameda K, et al. Among authors: ishizawa k. Blood. 2023 Jul 27;142(4):352-364. doi: 10.1182/blood.2022018597. Blood. 2023. PMID: 37146246
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.
Kawano Y, Kim K, Min CK, Koh Y, Ishizawa K, Kim SH, Ito S, Tanaka J, Uchiyama M, Ishida T, Kim JS, Moreau P, Martin T, Tada K, Risse ML, Suzuki K. Kawano Y, et al. Among authors: ishizawa k. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):e360-e367. doi: 10.1016/j.clml.2023.06.011. Epub 2023 Jul 3. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37479547 Free article. Clinical Trial.
Successful treatment of acute pancreatitis associated with late-onset acute liver GVHD after second allogeneic hematopoietic cell transplantation.
Hosokawa Y, Toubai T, Ohe R, Hosokawa M, Sato R, Yamada A, Aizawa K, Himuro M, Ito S, Yamamoto M, Peltier D, Ishizawa K. Hosokawa Y, et al. Among authors: ishizawa k. Blood Cell Ther. 2022 Jun 3;5(3):79-82. doi: 10.31547/bct-2021-023. eCollection 2022 Aug 25. Blood Cell Ther. 2022. PMID: 36712552 Free PMC article.
Exocrine Pancreatic Insufficiency Possibly Related to Atypical Chronic Graft-versus-Host Disease.
Hosokawa Y, Toubai T, Ohya K, Nagano Y, Ishizawa Y, Hosokawa M, Sato R, Watanabe S, Yamada A, Suzuki T, Aizawa K, Ito S, Onozato Y, Peltier D, Ishizawa K. Hosokawa Y, et al. Among authors: ishizawa k, ishizawa y. Case Rep Oncol. 2023 Sep 6;16(1):857-862. doi: 10.1159/000533381. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 37900836 Free PMC article.
586 results